...though it seems the initials are not really helping with misspelling, lol.
Sorry Ketone, but that was funny!
...though it seems the initials are not really helping with misspelling, lol.
K.C., I agreeSorry Ketone, but that was funny!
The reductions come because the COVID-19 pandemic has closed restaurants, cafeterias and tourist destinations that often feature chicken meals.
This new study shows why the antibody tests show such low numbers of infected people:
It might be another information used by those who want to vaccine the global population like :
- "SEE? It's soooo dangerous, we cannot know who have it !!"
- "Yeah, but... it also means that it's not so deadly, no?
- "OMG, don't you think about the potential mutations? And don't you think (with some tears in the eyes ) about all the people who could easily get infected and die because of that numbers?"
And there you have it. The official word on the COVID antibody test from official sources. It's yes, no, and maybe. Public health officials can SAY whatever they want to about antibody tests: a positive result means you're immune, it means you have an infection, it means you're walking on the moon eating a hot dog.
COVID Antibody Tests: Here Comes More Trickery and Fakery -- Sott.net
COVID antibody tests are going to become a focus, now that many states and nations have partially or fully lifted their lockdown restrictions. As we enter another chapter in the long book of Operation Coronavirus, authorities are trying to...www.sott.net
This could be a normal person's adaptation to uncover government officials and snitches. In case someone is a snitch, tell them to wear a mask. If they refuse to comply, then don't enforce.In one place he entered and somebody immediately shouted that he should have a mask. So he stopped and looked around to see what would happen. Then the other person said, "Oh well, come on then."
CureVac is a leading clinical stage biotechnology company in the field of messenger RNA (mRNA) technology with 20 years of expertise in developing and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines. CureVac has received significant investments, amongst others from dievini Hopp BioTech holding and the Bill & Melinda Gates Foundation. CureVac has also entered into collaborations with multinational corporations and organizations, including Boehringer Ingelheim, Eli Lilly & Co, Genmab, CRISPR Therapeutics, the Bill & Melinda Gates Foundation, CEPI and others. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA.
CRISPR/Cas9 – a specific, efficient and versatile gene-editing technology we can harness to modify, delete or correct precise regions of our DNA
Dr. Emmanuelle Charpentier, one of our scientific founders, co-invented CRISPR/Cas9 gene editing. Until then, people knew “CRISPR” only as an acronym for the Clustered Regularly Interspaced Short Palindromic Repeats of genetic information that some bacterial species use as part of an antiviral mechanism. Now, as a gene-editing tool, CRISPR/Cas9 has revolutionized biomedical research and may soon enable medical breakthroughs in a way few biological innovations have before.
CRISPR/Cas9 edits genes by precisely cutting DNA and then letting natural DNA repair processes to take over. The system consists of two parts: the Cas9 enzyme and a guide RNA.
Three main categories of genetic edits can be performed with CRISPR/Cas9:
DISRUPT
If a single cut is made, a process called non-homologous end joining can result in the addition or deletion of base pairs, disrupting the original DNA sequence and causing gene inactivation
DELETE
A larger fragment of DNA can be deleted by using two guide RNAs that target separate sites. After cleavage at each site, non-homologous end joining unites the separate ends, deleting the intervening sequence
CORRECT OR INSERT
Adding a DNA template alongside the CRISPR/Cas9 machinery allows the cell to correct a gene, or even insert a new gene, using a process called homology directed repair
"If scientists can dream of a genetic manipulation, CRISPR can now make it happen"
CRISPR/Cas9
www.crisprtx.com
Currently, several methods exist to deliver DNA or RNA to cells inside the body, which we can adapt to deliver CRISPR/Cas9 components. These methods fall into two broad categories: viral and non-viral. We are developing therapeutic programs based on technologies in both these areas.
Non-viral: Our efforts into non-viral delivery methods have focused on lipid nanoparticles (LNPs), which predominantly target the liver. We can encapsulate messenger RNA (mRNA) encoding Cas9 and guide RNA, and a donor DNA template if necessary, into LNPs to shuttle these components to the liver. We have entered into partnerships with the Massachusetts Institute of Technology (MIT) for LNP technology and CureVac for mRNA to support our liver-targeted programs
Viral: For other organ systems, including the muscle, lung and central nervous system, we have emphasized viral delivery, primarily using adeno-associated viral (AAV) vectors. These vectors can deliver DNA encoding for Cas9 and guide RNAs into specific tissues of the body. Through our collaboration with StrideBio, we aim to engineer novel AAV vectors that more specifically target individual tissue types and that can avoid pre-existing immunity
In Vivo
www.crisprtx.com
The great thing about gene therapy is that you can, in many cases, tackle the underlying cause of the disease. A lot of diseases today are just treated symptomatically, but with gene therapy, if the underlying cause is a gene defect, you can bring an intact copy of the gene into the patient or even repair the gene using genome editing tools like CRISPR-Cas.
To be able to do so, you need vehicles to deliver the gene. In most cases, although there are a number of non-viral approaches out there, the researchers use viral vectors. This makes a lot of sense because that’s what a virus does – it delivers genes to cells. We’re exploiting that feature of the virus, replacing the viral genes with the therapeutic gene, and using that viral vector to deliver the therapeutic gene to the target cells.
At the moment, there are three different viral vector types mainly used for gene-therapy approaches. One of them is the lentiviral vector, which has the advantage of integrating the gene into the cells, so it will stay there permanently. But lentiviral vectors also bear some risks because they can integrate into an unwanted position in the genome.
At the moment, lentiviral vectors are mainly used for ex-vivo therapies, in particular, because they are very good for transducing hematopoietic cells. Novartis’ Kymriah, for example, is a CAR-T therapy that uses a lentiviral vector to deliver the Chimeric Antigen Receptor (CAR) to T-cells outside of the patient. Then the modified cells are given back to the patient.
Second, there are adenoviral vectors, which were basically used when gene therapy started more than 20 years ago. They are still being used, but mainly for vaccination approaches. For example, there are some SARS-CoV-2 vaccines being developed at the moment with adenoviral vectors.
When we talk about in vivo gene therapies – actually delivering the therapeutic gene to the target cells inside the patient – then nearly always AAVs are used. The reason is that AAVs are non-pathogenic and the virus always needs the presence of a helper virus to replicate, and this makes it a lot safer than other viral vectors.
AAV is also a very interesting virus because it comes in a lot of different serotypes – different species of AAV. These serotypes correspond to distinctive structures on the surface of the virus, and that means that different tissues can be targeted. If you want to target neural tissue, for example, you’ll use a different AAV serotype than if you target the liver or muscles.
Another advantage of the AAV is that the particles themselves are very robust and very stable. They are easy to purify and once you’ve purified them, you can store them for a very long time without losing activity. All that makes them a nearly perfect tool for gene therapy.
How to Solve the Production Challenges of AAVs for Gene Therapy
In its rather short life, the gene therapy field has been on a rollercoaster of experiences. While the initial hype was dampened by failures in clinical trials, the field is now experiencing a strong comeback. What was once seen as a hope, is now becoming a reality. But producing viral vectors...www.labiotech.eu
This is why :I am sharing this just for our purposes. Discussing this with the people who listen to authorities has lost meaning a long time ago. Like this author says:
[...]
They tried to stop this virus, they found out that they can't. And now the vaccine is their only hope.
Welcome to Gattaca is closer and closer...German 'Moderna':
[...]
CRISPR Therapeutics:
[...]
Fun times!
Yes, what we learned thanks to the covid19 situation brought into light a way to bring changes in our DNA allowing blockades as enhancements. It reminds me of a session about the STO's influence on 3D life's evolution. It is clearer now.Well, just looking at what human beings can now do with viruses, it makes sense that higher forces would use viruses for guiding the evolution on Earth.
Sorry Ketone, but that was funny!